Investment News and Research RSS Feed - Investment News and Research

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. [More]

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round. [More]

Kineta, RLB Holdings form joint venture to address unmet medical needs

Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs. [More]
Sanofi Korea launches gut health product, Probi Digestis

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters. [More]

TSRI announces formation of Scripps Advance

The Scripps Research Institute (TSRI) today announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. [More]

AMETEK, Zygo enter into definitive merger agreement

AMETEK, Inc. and Zygo Corporation announced that they have entered into a definitive merger agreement under which AMETEK will acquire all of the outstanding shares of common stock of Zygo at a purchase price of $19.25 per share in cash, which represents a premium of 31% to Zygo's closing share price on April 10, 2014. [More]
Global clinical trial management system market expected to grow at 14% CAGR by 2019

Global clinical trial management system market expected to grow at 14% CAGR by 2019

According to a new market report published by Transparency Market Research "Clinical Trial Management System Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019," the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. [More]
Mayo Clinic collaborates with Enterprise Ireland to advance novel medical technologies

Mayo Clinic collaborates with Enterprise Ireland to advance novel medical technologies

Mayo Clinic today announced a five-year collaboration with Enterprise Ireland, the Irish enterprise development agency, to advance novel medical technologies originating from Mayo Clinic. [More]

Eliza receives grant by Workforce Training Fund to broaden training efforts and create new jobs

Eliza Corporation ("Eliza"), the pioneer and recognized leader in Health Engagement Management, has been awarded a grant by the Workforce Training Fund through the Commonwealth of Massachusetts, Executive Office of Labor and Workforce Development. [More]
Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection. [More]

Shiseido concludes joint venture agreement to expand Indonesia operations

Shiseido has concluded a joint venture agreement with PT Sinar Mas Tunggal, a group company of the Indonesian conglomerate, Sinar Mas Group. [More]
Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China. [More]
New book is an essential resource for academic scientists working in biomedicine

New book is an essential resource for academic scientists working in biomedicine

Cold Spring Harbor Laboratory Press is pleased to announce the publication of Connecting with Companies: A Guide to Consulting Agreements for Biomedical Scientists by Edward Klees, J.D. and H. Robert Horvitz, Ph.D. The book is an essential resource for academic scientists and physicians considering consulting work in biomedicine. [More]

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. [More]

Frost & Sullivan: Advancements in laser technology raise number of aesthetic procedures

Aesthetic procedures, though cost-intensive, have experienced increased growth over the past decade. With patients gradually shifting from more complicated, time-consuming invasive procedures to minimally invasive and non-invasive ones, surgical lasers in particular have turned out to be the most preferred choice for aesthetic applications. [More]

n3D and RBCC seek new finance partners to market and develop 3D bioprinting technology

Rainbow Coral Corp. and its joint venture partner, Nano3D Biosciences (n3D) are seeking out new finance partners to market and develop their 3D bioprinting technology worldwide. [More]

CPhI Russia Pharma Expo to be held at St. Petersburg from 16 to 17 April, 2014

Leading events organizer, UBM Live, along with partner RESTEC, announces that CPhI Russia @ IPhEB is returning for a second year to St. Petersburg, from 16th to 17th April 2014. The event will co-locate with ICSE, P-MEC and InnoPack, creating Russia's most comprehensive meeting point for the pharmaceutical industry. [More]
New lab at the Nencki Institute conducts research on neurodegenerative diseases

New lab at the Nencki Institute conducts research on neurodegenerative diseases

The Laboratory of Preclinical Studies of Higher Standard, the newest lab of the Neurobiology Center at the Nencki Institute in Warsaw, Poland, will conduct basic research aimed to explain molecular mechanisms responsible for neurodegenerative diseases. [More]
Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

​Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history. [More]